Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 321 followers
Latest posts
Last updated about 7 hours ago
Rainbows, pickleball and puppies: Inside the ‘enduring activism’ and ‘cautious optimism’ at ASH 2025
about 7 hours ago
People come to Orlando to escape. With Disney World, SeaWorld and Universal...
Teleflex inks $2B in divestment deals for OEM, urology and acute care units
about 9 hours ago
Two private equity firms, Montagu and Kohlberg, agreed to carve out Teleflex’s...
FDA clears 1st AI drug development tool for reading MASH images
about 10 hours ago
The FDA has cleared the first artificial intelligence (AI) drug development tool...
Medline sets terms for massive $5.37B Nasdaq IPO
about 10 hours ago
The medical device manufacturing and distribution giant could claim a valuation of...
ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma
about 12 hours ago
Exicure’s investigational small molecule succeeded in mobilizing key blood-forming cells in almost...
OSE narrows focus to conserve cash at expense of wider pipeline
about 12 hours ago
OSE Immunotherapeutics is prioritizing its lung cancer med Tedopi and its ulcerative...
Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug
about 14 hours ago
Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the...
ASH: J&J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma
about 15 hours ago
A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has...
ASH: Novartis details ianalumab's phase 3 win in rare blood disease
about 15 hours ago
Novartis is divulging details from ianalumab’s phase 3 win in a rare...
GSK cuts the cord on Ideaya collaboration, letting go of 2 programs
about 15 hours ago
GSK is walking away from Ideaya Biosciences after a five-year-long partnership that...
FDA steers cancer CAR-T developers toward randomized superiority trials in policy shift
about 16 hours ago
The FDA is raising the bar for approval of CAR-T cell therapies...
Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech
about 18 hours ago
Novartis has tapped an AI-enabled British biotech for a $1.7 billion biobucks...